New Biotech Business Models From 1999
This article was originally published in Start Up
Executive Summary
Advice of Counsel predicts the seven new business models that are likely to predominate in the months ahead, including "made to order" service deals; second-generation database companies; technology transfer from biotechs to big pharma; building a company to sell; holding onto a share of the upside of a late-stage product; skipping the high-risk phases of drug development; and diversifying the risk-reward tradeoff.